Gene · 57721
Papers4,298
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
821 to 840 of 4,298
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Overexpression of FTO inhibits excessive proliferation and promotes the apoptosis of human glomerular mesangial cells by alleviating FOXO6 m6A modification via YTHDF3-dependent mechanisms. | Front Pharmacol | 2023 | 37822879 | PubTator, text mining | PubMed |
| The Activation of M1 Macrophages is Associated with the JNK-m6A-p38 Axis in Chronic Obstructive Pulmonary Disease. | Int J Chron Obstruct Pulmon Dis | 2023 | 37822331 | PubTator, text mining | PubMed |
| Crosstalk of RNA methylation writers defines tumor microenvironment and alisertib resistance in breast cancer. | Front Endocrinol (Lausanne) | 2023 | 37818090 | PubTator, text mining | PubMed |
| The RNA methyltransferase METTL16 enhances cholangiocarcinoma growth through PRDM15-mediated FGFR4 expression. | J Exp Clin Cancer Res | 2023 | 37817227 | PubTator, text mining | PubMed |
| CSTF2 mediated mRNA N6-methyladenosine modification drives pancreatic ductal adenocarcinoma m6A subtypes. | Nat Commun | 2023 | 37816727 | PubTator, text mining | PubMed |
| In situ visualization of m6A sites in cellular mRNAs. | Nucleic Acids Res | 2023 | 37811887 | PubTator, text mining | PubMed |
| The predictive significance of a 5-m6A RNA methylation regulator signature in colorectal cancer. | Heliyon | 2023 | 37810844 | PubTator, text mining | PubMed |
| Remimazolam relieved the injury of hypoxia/reperfusion treated human embryo liver cell line through the targeting METTL3 mediated m6A modification of P53. | Heliyon | 2023 | 37809663 | PubTator, text mining | PubMed |
| The m6A reader YTHDC1-mediated lncRNA CTBP1-AS2 m6A modification accelerates cholangiocarcinoma progression. | Heliyon | 2023 | 37809459 | PubTator, text mining | PubMed |
| N6-methyladenosine methyltransferase KIAA1429 promoted ovarian cancer aerobic glycolysis and progression through enhancing ENO1 expression. | Biol Direct | 2023 | 37807062 | PubTator, text mining | PubMed |
| Association between ankylosing spondylitis and m6A methylation. | J Orthop Surg Res | 2023 | 37805597 | PubTator, text mining | PubMed |
| Methionine restriction sensitizes cancer cells to immunotherapy. | Cancer Commun (Lond) | 2023 | 37803877 | PubTator, text mining | PubMed |
| YTHDF2 facilitates aggresome formation via UPF1 in an m6A-independent manner. | Nat Commun | 2023 | 37803021 | PubTator, text mining | PubMed |
| Loss of YTHDF2 Alters the Expression of m6A-Modified Myzap and Causes Adverse Cardiac Remodeling. | JACC Basic Transl Sci | 2023 | 37791304 | PubTator, text mining | PubMed |
| STARD12/14 are diagnostic and prognostic biomarkers of lung adenocarcinoma associated with epigenetic regulation, immune infiltration and ferroptosis. | Int J Med Sci | 2023 | 37790851 | PubTator, text mining | PubMed |
| Deciphering m6A dynamics at a single-base level during planarian anterior-posterior axis specification. | Comput Struct Biotechnol J | 2023 | 37790241 | PubTator, text mining | PubMed |
| A Novel Trojan Horse Nanotherapy Strategy Targeting the cPKM-STMN1/TGFB1 Axis for Effective Treatment of Intrahepatic Cholangiocarcinoma. | Adv Sci (Weinh) | 2023 | 37789644 | PubTator, text mining | PubMed |
| WTAP-VIRMA counteracts dsDNA binding of the m6A writer METTL3-METTL14 complex and maintains N6-adenosine methylation activity. | Cell Discov | 2023 | 37789010 | PubTator, text mining | PubMed |
| M6A methylation modification in autoimmune diseases, a promising treatment strategy based on epigenetics. | Arthritis Res Ther | 2023 | 37784134 | PubTator, text mining | PubMed |
| FTO fuels diabetes-induced vascular endothelial dysfunction associated with inflammation by erasing m6A methylation of TNIP1. | J Clin Invest | 2023 | 37781923 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/57721/papers?page=42